Clinical Takeaway
People with PTSD and co-occurring substance use disorders who also use cannabis can still benefit meaningfully from trauma-focused treatments. Clinicians should not withhold or delay evidence-based PTSD care based on a patient’s cannabis use status.
#6 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis addresses a critical clinical gap by examining whether evidence-based PTSD treatments maintain efficacy in patients with concurrent cannabis use and comorbid substance use disorders, a population frequently excluded from or underrepresented in randomized trials. The findings provide empirical guidance for clinicians treating the substantial proportion of PTSD patients who use cannabis, informing whether standard trauma-focused protocols require modification or remain effective despite active cannabis use. Understanding treatment response across this common comorbidity pattern is essential for optimizing outcomes in real-world clinical settings where PTSD and polysubstance use frequently co-occur.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 This meta-analysis of individual patient data from trauma-focused PTSD treatment trials raises an important clinical question about whether cannabis use undermines evidence-based interventions in patients with co-occurring PTSD and substance use disorders, though the relatively small subset (drawn from four RCTs within a larger Project Harmony cohort) and potential selection bias warrant cautious interpretation of the findings. The heterogeneity of cannabis use patterns—including frequency, potency, route of administration, and whether cannabis is being used for self-medication versus recreation—represents a significant confounder that likely obscures meaningful clinical subtypes, and we should be careful not to treat “cannabis users” as a monolithic group in clinical decision-making. Additionally, the distinction between active cannabis use during treatment versus prior use history, as well as the role of concurrent psychosocial support and medication management, may substantially modify treatment outcomes in ways the current analysis may not fully capture. For practitioners, this work suggests that cannabis use should not automatically be viewed as a contraind